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Abstract 
The essential roles of proteins of the serpin family in many physiological processes, along with new discoveries of their unique folding properties, 
have attracted intense interest in recent years. Many serpins display unusual mobile behavior attributed to rearrangements of a-helical or /J-sheet 
domains, whereby large scale transitions accompany a variety of functions, including inactivation. This unusual behavior was first recognized with 
the X-ray structure of modified al-proteinase inhibitor. Subsequent experiments, including new X-ray structures, have revealed a surprising variety 
of conformations which are functionally important but only partially understood. We review here experimental evidence for conformations relevant 
to the serpin inhibitory mechanism. 
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1. Introduction 
The search for the spatial structure of a serpin (the 
acronym denotes one superfamily of SERine Proteinase 
INhibitors) in an active conformation began with the 
determination of the X-ray structure of proteolytically 
modified al-proteinase inhibitor (alPI) [l], which re- 
vealed the occurrence of a large scale transition after 
cleavage. A variety of X-ray structures have been deter- 
mined since, including that of the common deficiency 
S-variant of cllP1 [2], the inhibitor al-antichymotrypsin 
(ACHY [3]), equine elastase inhibitor (HLEI [4]), the 
non-inhibitory serpin ovalbumin (PLAK [5]; OVAL [6]), 
the latent form of plasminogen activator inhibitor PAI- 
[7], uncleaved antichymotrypsin ACHY [8], and un- 
cleaved antithrombin III (AT111 [9,10]). Of these struc- 
tures, only the latter three (PAI-1, ACHY, and ATIII) 
are inhibitory serpins not modified by proteolytic cleav- 
age. The structures distinguished the serpins from other 
standard mechanism serine proteinase inhibitors (BPTI, 
among others; see Bode and Huber [l I]), which other- 
wise are typically rigid with a single, well defined ‘canon- 
ical conformation’ at the binding site. None of the serpin 
structures, however, show a canonical conformation at 
the binding site. Instead, they show a binding loop which 
can adopt a variety of conformations. The structure of 
AT111 [9,10] shows a structure most compatible with 
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binding to its target protease, and demonstrates also a 
conformation suggested from a variety of experiments 
[12-171. In this minireview, we summarize these experi- 
ments, together with the serpin crystal structures, while 
attempting to rationalize aspects of the serpin inhibitory 
mechanism not yet observed by direct structural determi- 
nation. 
1. I. Serpin discovery 
A proteinase inhibitor in human plasma was discov- 
ered in 1894 [ 181, isolated in 1955 [19] and later named 
ollP1. Hunt and Dayhoff [20] recognized its sequence 
homology to ovalbumin and ATIII, thus identifying the 
serpin superfamily. Most serpins have been isolated from 
plasma, are variously glycosylated and have molecular 
weights from 45 to 100 kDa. HLEI and PAI- have been 
shown to exist in unglycosylated forms in the cytosolic 
fraction [21], and still others, such as ATIII, PAI- and 
proteinase nexin I, can be found in the extracellular ma- 
trix. 
A recently discovered serpin is cowpox virus crmA 
(cytokine response modifier) [22], which suppresses host 
response to infection via inhibition of interleukin- 1 -/I- 
converting enzyme [23]. Its apparent molecular weight is 
38 kDa due to several deletions, mostly on the N-termi- 
nal side of the active site, among them the deletion of 
helix D (see Fig. 1). Others include ‘Serpl’ from myxoma 
virus and malignant rabbit fibroma pox virus [24]. 
Although many serpins function as proteinase inhib- 
itors, others are hormone transporters, peptide hormone 
precursors or have no known function. Clinical studies 
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have revealed many naturally occurring deficiency mu- 
tants of serpins, primarily of ollP1 and ATIII, showing 
the importance of these serpins in lung and blood proc- 
esses (for details and further references see [25,26]). 
1.2. Receptor binding and plasma clearance 
A major function of serpins is to provide a tag for the 
removal of proteolytic enzymes from circulation via cel- 
lular receptors, sometimes supposed to occur when com- 
plexation with the serpin reveals a receptor recognition 
site [27]. Three types of receptor have been described: (i) 
the a2-macroglobulinllow density lipoprotein (a2Ml 
LDL) related protein receptor, (ii) a proposed serpin- 
enzyme complex (SEC) receptor, and (iii) the urokinase 
receptor [28]; the latter recognizes and binds urokinase 
independent of serpin binding (PAI-1). 
The a2MILDL receptor is implicated in hepatic up- 
take of proteinaseeinhibitor complexes, as well as pro- 
teinase-inhibitor-receptor complexes, from circulation 
and extracellular space. Evidence for its involvement in 
internalization and degradation of complexes comes 
from experiments that show blocking of PAI-l-enhanced 
degradation by addition of anti-a2M receptor antibody 
in monocytes [29]. 
A serpinenzyme complex (SEC) receptor has been 
proposed to recognize a specific pentapeptide sequence 
highly conserved among serpins, based on studies show- 
ing that analogous synthetic peptides block the binding 
and internalization of serpinenzyme complexes by 
HepG2 cells, and by the observation that such peptides 
bind specifically and saturably to neutrophils, mon- 
ocytes, and hepatoma derived hepatocytes. The recogni- 
tion sequence, buried and completely inaccessible in 
crystal structures of serpins, is supposed to become ac- 
cessible after a serpin conformational change upon com- 
plexation with the protease. This putative change must 
be related to the transition after cleavage, since cleaved 
ollP1 competes with the a1PIIelastase complex for bind- 
ing ([30] and refs. therein), which is not easily reconcila- 
ble with the known crystal structure of alPI. 
1.3. Serpin interaction with heparin 
ATIII, heparin cofactor II (HCII), protease nexin I, 
protein C inhibitor, and PAI- are relatively weak bind- 
ing inhibitors of thrombin but bind tightly after addition 
of heparin. The heparin-AT111 complex binds thrombin 
1 ,OOO-fold more tightly than AT111 alone. A heparin pen- 
tasaccharide interacts with serpins via four of its sulfate 
groups, probably at helix D in AT111 and HCII ([25] and 
refs. therein), and at helix H in protein C inhibitor 
([31a,b]; Fig. l), as identified by chemical modification 
and naturally occurring mutant studies. The enhance- 
ment of thrombin-serpin binding with heparin involves 
both induced conformational changes and bridging in- 
teractions. The minimal pentasaccharide heparin ac- 
counts for nearly all of the binding energy of heparin to 
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Fig. 1. Ribbon-type stereo representation [56] of alPI. 
ATIII, accelerates thrombin inhibition and promotes in- 
teraction with factor Xa, attributed to the induction of 
a conformational change in AT111 [32]. Heparin binding 
also depends on the degree of glycosylation of AT111 
[33], and involves the N-terminus and other regions of 
the protein [34]. There is also evidence of heparin de- 
pendent domain rearrangement or unfolding [35]. 
1.4. Serpin interaction with vitronectin 
Vitronectin, reviewed in detail by Preissner [36], forms 
complexes with serpins, heparin, and target proteases. It 
acts as a non-competitive inhibitor of the heparin-accel- 
erated reaction of AT111 with thrombin and factor Xa. 
Interactions of vitronectin in ternary complexes of ser- 
pin, thrombin and vitronectin presumably involve disul- 
fide bridges with thrombin. Vitronectin binds directly to 
PAI-1, however, mainly through ionic interactions, 
which stabilizes PAI- in its inhibitory form, although 
other sites have also been suggested ([36] and refs. 
therein). Vitronectin itself binds heparin at a site adja- 
cent to its PAI- binding site. 
2. X-ray structures 
The first X-ray structure determination of a serpin was 
of the reactive site modified M-form of human al-an- 
titrypsin (alp1 * * denotes cleavage at the reactive site , 
Met358-Ser3s9 [1,37]). The structure showed that the 
cleavage is followed by a conformational rearrangement 
whereby the residues at the cleavage site (PI, Pl’) become 
separated by 70 A after incorporation into P-sheet struc- 
tures. The nature of this rearrangement was suggested by 
Lobermann et al., but was first observed in part in the 
X-ray structure of proteolytically modified ovalbumin, 
PLAK [5]. The structure of intact ovalbumin followed 
[6], showing an a-helical structure for the strand corre- 
sponding to the binding site of serpin inhibitors, similar 
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Fig. 2. Schematic diagrams ofg-sheet A configurations in different serpins. The binding loop and strand s4A, partially absent in plakalbumin, adopts 
a helical conformation in ovalbumin but is an integral part of sheet A in cleaved alPI. Experimental results suggest that a partial insertion of s4A 
into sheet A is required for inhibitory activity of alPI. 
to the structure of intact ACHY [8]. The structure of the 
latent form of PAI- [7] showed incorporation of the 
binding loop into a /?-sheet without cleavage, 
demonstrating the structural basis for latency. The re- 
cently described structures of intact AT111 [9,10] show 
partial incorporation, consistent with proposals based 
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on a variety of experiments [14], although these struc- 
tures also leave unanswered many questions regarding 
the serpin inhibitory mechanism. We have recently re- 
viewed the structures of alPI*, PLAK, OVAL, and la- 
tent PAI- [26]. 
2.1. Cleaved alPI* 
The cleavage at the binding loop of cllP1 by chymo- 
trypsinogen A [37] facilitates crystallization, probably by 
allowing a normally flexible binding loop to be incorpo- 
rated into existing secondary structures, a transition 
often referred to as the S+R (strained+relaxed) transi- 
tion [38,39]. Cleaved ollPI* is folded into a highly or- 
dered structure, with threep-sheets (A-C), nine a-helices 
(A-I) and six helical turns (Fig. 1; h stands for helix, s 
for p-sheet). The six stranded, mostly antiparallel /3- 
sheets A and B are the most extensive structures of the 
molecule. Three strands of sheet B, along with helix B, 
provide the hydrophobic core highly conserved among 
serpins. One of these, strand s4B, is entirely buried and 
contains the putative recognition site for the proposed 
SEC receptor [30]. 
Sheet A is packed over the hydrophobic core, with the 
strands orientated perpendicular to the P-strands of 
sheet B (Fig. 1). Sheet A has a large number of conserved 
hydrophobic interactions and several hydrogen bonds 
with the mostly hydrophobic core. Several conserved 
hydrophobic contacts exist between strands l-3 of sheet 
A and helix F. Prior to proteolytic modification, how- 
ever, p-sheet A lacks its central strand (s4A), which only 
after cleavage can adopt the position observed in the 
crystal structure. 
Sheet C is also implicated in this structural transition, 
since strand 1 includes the residues immediately C-termi- 
nal to the cleavage site. Sheet C is exposed to the solvent 
on one side, and is packed with hydrophobic contacts on 
the other to sheet B. 
Most of the rest of the molecule is folded into 01- 
helices. Helix F partially covers sheet A, including strand 
s4A, and so must move during or following the S+R 
transition. Helix D, absent in the viral serpins, forms the 
likely heparin binding site. Helices G and H are found 
under and behind/?-sheet B (in the orientation of Fig. l), 
covering the putative recognition site for the SEC recep- 
tor [30]. Any reorganization of the molecule to expose 
the recognition site must involve the movement of these 
helices away from their hydrophobic packing against 
sheet B. 
2.2. Ovalbumin 
Ovalbumin has no known inhibitory function and 
does not undergo the S-+R transition [38,39] characteris- 
tic of the inhibitors. Plakalbumin, a cleaved ovalbumin, 
was therefore expected to provide a model for the overall 
structure of intact serpins, particularly for B-sheet A. 
Indeed, its structure [5] differs from alPI*, primarily 
through the absence of P-strand s4A in sheet A [l]. Sheet 
A was found to have a nearly ideal 5 stranded B-sheet 
geometry (Fig. 2), with antiparallel interactions between 
strand pairs s5A-s6A and s2A-s3A, and parallel interac- 
tions between s3A-s5A and slA-QA. Superposition of 
the conserved hydrophobic core regions of cllP1 and 
plakalbumin showed that the S+R conformational tran- 
sition is accompanied by a translation of strands slA- 
s3A relative to the rest of the molecule; strands s5A and 
s6A have nearly identical conformations and positions 
as in alPI. Helix F is translated in parallel with strands 
slA-s3A. The flatness of sheet A may be a prerequisite 
for this reformation of sheet A to occur. 
In plakalbumin, the residues from the turn between 
s4A and s5A up to the cleavage site emerge from the 
sheet and lie along the protein surface. The upper seg- 
ments of strands 3A and 2A have identical positions as 
in alPI, leaving a small opening which in cllP1 contains 
the first residues of s4A, but here is filled with ordered 
water molecules. Residue 345, at the hinge site, is an 
arginine in ovalbumin and angiotensinogen, but is other- 
wise conserved as Thr, Ser, Val, or Ala among all inhib- 
itory serpins. Wright et al. [5] pointed out that a small, 
preferably hydrophobic residue at this site is a prerequi- 
site for the insertion of strand s4A into sheet A. 
The 1.9 A structure of intact ovalbumin was the first 
X-ray structure of an intact serpin to be determined [6]. 
The strand from P9 to Pl’ adopted an a-helix structure. 
This was contrary to expectations based on an assump- 
tion that all serpins would have the canonical structure 
of small serine proteinase inhibitors at the binding site, 
but was consistent with a strongly predicted a-helix pro- 
pensity for the loop in serpins, including the inhibitor 
cllP1 [40]. Since cleavage is thought to require a canoni- 
cal conformation, this helix presumably must partially 
unfold prior to or during protease binding and cleavage. 
The similarity of the structure of the ovalbumin reac- 
tive loop and that of an intact inhibitory serpin structure 
is uncertain, since ovalbumin is not an inhibitor and does 
not undergo the post-cleavage structural rearrangement. 
All known structures of ‘standard mechanism’ serine 
proteinase inhibitors adopt stable canonical conforma- 
tions [ll] at the binding loop. In contrast, inhibitory 
serpin structures have been determined where the bind- 
ing loop conformations may have been artificially stabi- 
lized, and a helical conformation may be influenced by 
crystallization conditions [41,42]. A structure of intact 
antichymotrypsin was recently reported [8] with strand 
s4A in a helical conformation, so at least a propensity for 
this conformation [l] may well be characteristic of the 
serpin family. 
2.3. Latent PAI- 
The mobility of sheet A, strand s4A, and sheet C was 
demonstrated anew with the structure of latent human 
PAI- [7]. The crystal structure showed that strand s4A 
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is integrated into sheet A from the ‘hinge’ at P15 to 
residue Va13” (P4) in the latent form. The residues C- 
terminal to the cleavage site, comprising strand slC in 
alPI*, are not part of sheet C and instead approach 
strand s5B from below the p-ribbon of sheet C, rather 
than from above as in the alPI* structure. If the confor- 
mation of proteinase bound PAI- is to resemble that 
suggested by the plakalbumin and ovalbumin structures, 
strands s3C and s4C of the p-ribbon must move to ac- 
commodate the transition to the latent form. These were 
found to be disordered in latent PAI- 1. As with ovalbu- 
min, the information from this structure relative to the 
serpin inhibitory mechanism is unclear, since the sponta- 
neous transition to a ‘latent’, non-inhibitory state is not 
a general property of serpins [43], although AT111 also 
exhibits a latent state [lo]. 
2.4. Intact antithrombin III 
Schreuder et al. [9] and Carrel1 et al. [lo] have reported 
3 A resolution structures of dimers of antithrombin III 
(ATIII). The authors disagree about the form of one 
monomer in the dimer (whether it is cleaved or, more 
likely, intact but latent), and Schreuder et al. [9] report 
that the binding loop of the other monomer is partially 
inserted into sheet A and involved in crystal contacts, 
consistent with suggestions from some experiments (see 
below). Carrel1 et al. [lo] report fragmented electron den- 
sity at the region of putative partial insertion. This form 
has a conformation more suited to docking with a serine 
proteinase but still lacking a canonical conformation [ 1 l] 
at the binding site, further evidence of the flexibility of 
the binding loop. 
3. Conformations of the ‘inhibitory state’ 
The inhibitory state, that is, a non-latent state of an 
inhibitory serpin, may involve a variety of conforma- 
tions. The serpin binding loop has occcurred in several 
different conformations in X-ray structures, and it is not 
possible at present to determine whether different stages 
of protease inhibition or binding involve unique confor- 
mations. This is in contrast to the small serine proteinase 
inhibitors [l 11, which, apart from small local changes in 
cleaved forms, are unchanged upon complexation. Crys- 
tallographic and other experimental evidence for serpins 
indicates rather a picture of an inhibitor with a flexible 
binding loop which may be induced to adopt a canonical 
conformation either by complexation or prior to it, al- 
though it is not clear whether a canonical conformation 
must be retained after initial binding. In addition, partial 
insertion of the loop into sheet A must be possible for 
inhibitory activity (see below). 
3.1. Experimental clues to conformational properties 
The occurrence of the S + R transition [39] upon 
cleavage is accompanied by both a dramatic increase in 
thermal stability, from 58°C to 85°C for AT111 and 
alPI, and also increased resistance against guanidine 
hydrochloride induced unfolding [ 121. This has been seen 
in all inhibitory serpins tested as well as in the non- 
inhibitory TBG and CBG [44]. Ovalbumin and angioten- 
sinogen notably lack this transition [38]. 
The increase in thermal stability parallels effects ob- 
servable with fluorescence emission, CD, NMR, and FT- 
IR spectroscopy. These can thus be used to characterize 
conformations induced by experiment and compare 
them with naturally occurring conformations. In CD 
experiments, cleavage increases the negative ellipticity 
around 220 nm, attributed to an increase in secondary 
structure [12]. FT-IR studies indicate an increase in anti- 
parallel B-structure [45]. NMR studies also show greater 
stability due to increased antiparallel/?-sheet interactions 
[46]. Ovalbumin and angiotensinogen also lack these fea- 
tures [47], and ovalbumin shows characteristics interme- 
diate between those of typical inhibitory serpins [38,47]. 
Perhaps the most revealing and unique experiments 
involve the complexation of short polypeptides with in- 
tact serpins [12], often referred to as peptide annealing 
experiments (see below). These peptides, designed to 
mimic lengths of strand s4A, can assume the role of 
strand s4A in the local refolding of sheet A. Accessibility 
of sites in the binding loop to proteolytic cleavage [15] 
or antibody binding [48] have also been used to evaluate 
models of conformations of the inhibitory state. Simi- 
larly, differing inhibitory properties of strand s4A mu- 
tants suggest requirements for inhibitor models. For ex- 
ample, the replacement of Thr345 with Arg in alP1 
[ 13,491, as found in ovalbumin, renders cllP1 a substrate. 
Based on studies of naturally occurring mutants of the 
Cl inhibitor, Skriver et al. [50] showed further effects 
also involving the P12 and PlO sites. Finally, since a 
major pathway for aggregation involves the complexa- 
tion of strand s4A of one molecule in sheet A of another, 
aggregation studies also provide structural information 
[ 12,15,48,49] and additionally demonstrate the mecha- 
nism of a type of serpin deficiency mutant syndrome. 
Several states of serpins may be distinguished, for ex- 
ample (i) native, capable of inhibition, (ii) substrate, 
when distinguishable from an inhibitory state, (iii) 
cleaved and (iv) latent states, the latter as in PAI- [7,43]. 
These may be well defined conformations (Fig. 2) but 
may also represent sets of interconverting flexible states. 
If the latter case obtains, the native serpin would be 
flexible, and the binding loop may adopt a canonical 
conformation only upon complexation, accompanied by 
partial insertion of strand s4A into sheet A at some stage 
of the inhibition. This is consistent with a variety of 
results, including the failure to observe a canonical con- 
formation in the crystal structure of intact Achy [8] and 
with the occurrence of partial insertion in the crystal 
structures of dimeric AT111 [9. lo]. 
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3.2. Peptide annealing experiments 
The first peptide annealing experiment involved the 
complexation of the serpin with a synthetic peptide mim- 
icking strand s4A [ 121. This induced a state in ollP1 which 
no longer had inhibitory properties, but instead led to 
substrate-like cleavage at the reactive site by trypsin. The 
complex shows CD spectra and denaturation stability 
similar to that of the cleaved form, indicating that the 
peptide binds in the position of strand s4A as seen in the 
X-ray structure of alPI*. Similar results were obtained 
for AT111 [17], which shows reduced heparin affinity 
when complexed with an annealed peptide. Conversely, 
incubation of AT111 with high affinity heparin and the 
tetradecamer peptide retards peptide-AT111 complex 
formation. 
Complexation with the tetradecameric peptide thus 
prevented a transition of alP1 to an inhibitory form. 
This suggested an explanation for the conservation of 
small hydrophobic residues at position 345 and for the 
results of the mutant studies, namely, that strand s4A 
must be at least partially inserted into P-sheet A for 
inhibition. The peptide, like the P14 mutant 
(Thr345 + Arg), prevents this insertion. The extent of 
insertion is significantly narrowed by further peptide an- 
nealing experiments [14]. Beginning with the full length 
tetradecamer peptide, peptides progressively shortened 
at the N-terminus were synthesized and complexed with 
intact ollP1. The resulting complexes were tested for in- 
hibitory activity, with the hypothesis that inhibition 
should occur when the complexed peptide is short 
enough to allow the necessary degree of insertion. Based 
on the observed onset of inhibition with a unadecamer 
peptide blocked with an acetyl protecting group, a model 
including insertion of Thr345 and maximally part of resi- 
due 346 is supported (Fig. 3). 
3.3. Models for the inhibitory form(s) 
Detailed models require a number of assumptions in 
addition to the experimental constraints. First, the con- 
formation of the binding loop in the serpin-inhibitor 
complex most likely adopts the canonical conformation 
[l l] of standard mechanism inhibitors [51] at binding. 
This assumption is quite likely a good one, since all 
X-ray structures of the small serine protease inhibitors 
show this conformation with only small deviations, al- 
though the loop in the isolated inhibitor may be flexible, 
like that of eglin c [52,9]. Second, the partial insertion of 
strand s4A in the inhibitory form is assumed to include 
only P14(Thr345), as indicated by the peptide annealing 
results. This requirement need not be fulfilled simultane- 
ously with the occurrence of a canonical conformation, 
since the partial insertion may occur after esterification 
of the scissile peptide bond in the enzyme. If simultane- 
ous, however, a third assumption, that sheet C is un- 
changed in the inhibitory form, greatly reduces the possi- 
ble conformations. This third hypothesis is rather weakly 
Fig. 3. One possible model for an inhibitory complex of alPI and a 
blocked unadecamer peptide. A completely inserted synthetic peptide 
would only allow partial insertion, including P14 (Thr’45) and possibly 
part of P13 (GIL?). 
supported by the observation that all X-ray structures of 
cleaved serpins have very similar structures and con- 
served hydrogen bonding patterns in the sheet C region. 
An appropriate model would then represent the confor- 
mation of the inhibitor in the serpin-enzyme encounter 
complex, and so is further restricted by the requirment 
that it must fit into the active site of the enzyme. For 
alPI, it must be possible to dock a model to its target, 
leukocyte elastase. Further, it must be possible to dock 
a model of the Pittsburgh variant (Met3’* + Arg) to the 
structure of thrombin, the more restricted active site of 
which provides stricter restraints. 
3.4. Sheet A 
Lobermann et al. [l] speculated that P-sheet A is desta- 
bilized in the intact inhibitor to allow strand insertion. 
The structure of PLAK [5] as well as molecular dynamics 
simulations [53] suggested a five-stranded /?-sheet struc- 
ture for an intact form. An inhibitory complex with a 
peptide (s4A mimic) bound serpin (Fig. 3), however, 
most likely has a six-stranded p-sheet structure, where 
the peptide adopts the conformation of strand s4A as 
seen in alPI*. This, along with the inability to form 
peptide complexes with ovalbumin, suggests that ovalbu- 
min is not conclusive as a model for B-sheet A of an 
intact inhibitory serpin, and that the destabilization of 
sheet A may involve deviations from the ideality of the 
ovalbumin A sheet. The structure of the sheet in intact 
Achy [8] is, however, not obviously destabilized (D. 
Christianson, personal communication), and sheet A in 
AT111 [9] is consistent with models of a ‘zipper’ like 
insertion [53] whereby sheet A is open below the insertion 
point and intact elsewhere. 
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3.5. Implications of inhibitory models for the inhibitory 
mechanism 
Models of inhibitory serpin structures are based on the 
assumption that serpins bind to their target enzymes 
much as the standard mechanism protein inhibitors do 
[11,51], that is, that at least in an encounter complex the 
binding loop adopts the canonical conformation. 
Whether such a conformation exists prior to binding or 
is induced by binding is unknown. Three descriptions are 
discussed: (i) a folding model, which classifies the inhib- 
itory state as an intermediate folding state; (ii) a pre- 
equilibrium model [33,50]; and (iii) an induced fit model. 
The latter two models describe the succession of steps 
leading to a canonical conformation, and are applicable 
independent of considerations of the folding model. 
In the folding model the serpin is folded and secreted 
from the cell in a metastable conformation which, if not 
readily bound to its target proteinase, proceeds to a sta- 
ble inactive form, perhaps latent or cleaved. The fact that 
latent and cleaved forms are significantly more stable 
than active conformations, and that there is no known 
physiological mechanism to reactivate latent PAI-I by 
an energetically expensive refolding, support such a fold- 
ing model. An active inhibitor, then, is considered an 
intermediate folding state, which is either identical to an 
encounter complex conformation, or may adopt the con- 
formation upon binding. 
cleaved or peptide-complexed AT111 [55], whereas the 
native form was not recognized. Heparin binding was 
excluded as a cause of the relevant change. The epitopes 
are likely to be at sites which in the native state are either 
internal, not tightly packed, or in a different conforma- 
tion [55]. The authors argue that a native form which has 
a ‘pre-inserted’ binding loop should be recognized along 
with the cleaved or latent forms. However, the cleaved 
and latent forms have different degrees of insertion. PAI- 
1 exhibits epitopes in the cleaved and latent form which 
are not seen in the active species [29]. These lie mostly 
on the rear side and the upper left part of sheet A and 
the whole structure (Fig. 1). HF, hE and slA are equally 
accessible in all conformations, suggesting that these re- 
gions are almost unaffected by structural changes. One 
particularly significant result is that a2AP inhibits tryp- 
sin and chymotrypsin at adjacent reactive sites [54], sup- 
porting the view that the enzyme plays an important role 
in inducing conformational changes in serpins. 
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are: (i) the ‘pre-equilibrium’ model, whereby the inhibi- 
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ation with its target, and (ii) the ‘induced fit’ model, 
whereby complexation with the protease induces confor- 
mational change or rigidification leading to an inhibitory 
complex. The two models are not mutually exclusive, 
and differ primarily in the degree to which the enzyme 
influences adoption of a bound conformation. Consider- 
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